Related content

Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1101-1113

Bentham Science Publishers

Access to resources Recommend Favorite

Animal Models for Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 9, 2014-11 ,pp. : 1580-1594

Bentham Science Publishers

Access to resources Recommend Favorite

Elevated Homocysteine Levels in Parkinson's Disease: Is there Anything Besides L-Dopa Treatment?

By  

Current Medicinal Chemistry, Vol. 17, Iss. 3, 2010-01 ,pp. : 213-221

Bentham Science Publishers

Access to resources Recommend Favorite

L-Dopa Prodrugs: An Overview of Trends for Improving Parkinson's Disease Treatment

By  

Current Pharmaceutical Design, Vol. 17, Iss. 32, 2011-11 ,pp. : 3482-3493

Bentham Science Publishers

Access to resources Recommend Favorite

L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 11, Iss. 4, 2011-12 ,pp. : 305-320

Bentham Science Publishers

Access to resources Recommend Favorite